OncoMatch/Clinical Trials/NCT06448026
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).
Is NCT06448026 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cemiplimab and Cetuximab for locally recurrent oral cavity squamous cell carcinoma.
Treatment: Cemiplimab · Cetuximab — To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: curative-intent therapy (including surgery, post operatory radiation, and/or chemotherapy) — curative
Disease recurrence at least 3 months after completion of curative-intent therapy (including surgery, post operatory radiation, and/or chemotherapy)
Cannot have received: anti-PD-1/PD-L1 agent
Any prior treatment with an anti-PD1/PD-L1 agent
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dL (transfusions permitted); Absolute neutrophil count ≥ 1 x 10^9/mL; Platelets ≥ 80 x 10^9/mL
Kidney function
Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation
Liver function
AST and ALT ≤ 3 x ULN; Total bilirubin ≤ 1.5 x ULN or ≤ 3.0 x ULN and primarily unconjugated if subject has a documented history of Gilbert's syndrome or genetic equivalent
Laboratory measurements, blood counts: Hemoglobin ≥ 9 g/dL. Red blood cell transfusions are permitted to meet the hemoglobin inclusion criteria; Absolute neutrophil count ≥ 1 x 10^9/mL; Platelets ≥ 80 x 10^9/mL. Laboratory measurements, renal function: Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation. Laboratory measurements, hepatic function: AST and ALT ≤ 3 x ULN; Total bilirubin ≤ 1.5 x ULN or ≤ 3.0 x ULN and primarily unconjugated if subject has a documented history of Gilbert's syndrome or genetic equivalent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify